Veterinary Medicines

Gabbrocol 100 mg/g pó para administração oral para vitelos e suínos

Authorised
  • Paromomycin sulfate
Download as PDF

Product identification

Medicine name:
Gabbrocol 100 mg/g pó para administração oral para vitelos e suínos
Active substance:
  • Paromomycin sulfate
Target species:
  • Pig
  • Cattle (calf)
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Paromomycin sulfate
    100.00
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Oral powder
Withdrawal period by route of administration:
  • Oral use
    • Pig
      • Meat and offal
        30
        day
    • Cattle (calf)
      • Meat and offal
        30
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA07AA06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ceva Saude Animal Produtos Farmaceuticos E Imunologicos Lda.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva Salute Animale S.p.A.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 1163/01/18NFVPT
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 9/06/2023
Updated on: 10/06/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."